Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,012 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,920 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 |
| clinicaltrials |
| NCT05182866 | ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer | unknown | Phase 2 | 9 | Rakuten Medical, Inc.INDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT03784066 | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity(DUTRELASCO) | unknown | Phase 1 / Phase 2 | 21 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT04444869 | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer(ENID) | unknown | Phase 2 | 28 | University of Missouri-ColumbiaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05145907 | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors | unknown | Phase 2 | 133 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06364826 | Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma | unknown | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06362694 | Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy | unknown | Phase 2 | 10 | Saint Petersburg State University, RussiaOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04830267 | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC | unknown | Phase 2 | 39 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06259721 | Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05011227 | Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04597476 | A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck | unknown | Phase 2 | 119 | Hi-Q Marine Biotech International, Ltd.INDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06235918 | Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 30 | Xiang LuOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05675605 | A Study of TY-1091 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 248 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03146650 | Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer | unknown | Phase 2 | 25 | Northwestern UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03708822 | Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04398524 | A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC | unknown | Phase 2 | 65 | ISA PharmaceuticalsINDUSTRY | 9 | Jan 16, 2024 | clinicaltrials |
| NCT03669718 | A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | unknown | Phase 2 | 194 | ISA PharmaceuticalsINDUSTRY | 13 | Dec 29, 2023 | clinicaltrials |
| NCT06170697 | Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 46 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06156878 | PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05576272 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 460 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06107114 | Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma(CZCNRHNSCC) | unknown | Phase 2 | 52 | Xuekui LiuOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06142318 | Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 66 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02624128 | Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck(V-CHANCE) | unknown | Phase 2 | 39 | National Cancer Institute, NaplesOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT04277858 | Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.(NECTORS) | unknown | Phase 2 | 60 | Nader SadeghiOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06081582 | Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC | unknown | Phase 2 | 33 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT05626829 | Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | unknown | Phase 2 | 18 | Jian GuanOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05520814 | PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial | unknown | Phase 2 | 50 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06023875 | Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma(NCCCNRHNSCC) | unknown | Phase 2 | 30 | Xuekui LiuOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT06016400 | Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma | unknown | Phase 2 / Phase 3 | 412 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05102292 | The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation | unknown | Phase 1 / Phase 2 | 25 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04156698 | Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma | unknown | Phase 2 | 51 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04297995 | Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors | unknown | Phase 2 | 131 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05981157 | Anrotinib and Tirelizumab in First-line Treatment of RM-NPC | unknown | Phase 2 | 27 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05783921 | A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 28, 2023 | clinicaltrials |
| NCT05965154 | Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 22 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jul 28, 2023 | clinicaltrials |
| NCT03925090 | Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03001570 | Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District(FAMOSO) | unknown | Phase 2 | 10 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05913414 | Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 120 | Sun Yat-sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04072107 | EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)(EP-STAR) | unknown | Phase 2 | 110 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04221516 | Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 52 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05898256 | Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Guangxi Medical UniversityOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05861557 | Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 23 | Tianjin Medical University General HospitalOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT04586088 | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | unknown | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05229315 | PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma | unknown | Phase 2 | 45 | XIANG YANQUNOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05803915 | Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy | unknown | Phase 2 | 57 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Oct 2, 2024source: clinicaltrials